NxStage Medical (NSDQ:NXTM) named Robert Funari to replace Philippe Chambon as non-executive chairman after 15 years on the medical device company’s board of directors.
NxStage Medical taps Funari to replace Chambon as chairman | Personnel Moves
Cooley LLP
Devices plus drugs may mean an earlier payoff
Michael Cima
Companies combining valuable devices with known drugs may be able to land a high-value exit before ever hitting the market, MIT researcher Michael Cima told a group of medical device industry leaders today.
Speaking at the Cooley Medical Device Growth conference in Boston, Cima urged med-tech companies and investors to consider drug-device combinations, acknowledging a higher up-front risk with the potential for an earlier and larger reward.
